Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 660-666

  Merabet, Nassiba ^a   Bellien, Jeremy ^a,e,f   Glevarec, Etienne ^a,f   Nicol, Lionel ^a,f   Lucas, Daniele ^b   Remy Jouet, Isabelle ^a,f   Bounoure, Frederic ^c,f   Dreano, Yvonne ^b   Wecker, Didier ^d   Thuillez, Christian ^a,e,f   Mulder, Paul ^a,f  

^a UNIVERSITÉ DE ROUEN   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d BRUKER BIOSPIN GMBH   (Germany)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f Institute for Biomedical Research of Rouen   (France)

Author keywords

Epoxyeicosatrienoic acids; Heart failure; Left ventricular function; Myocardial perfusion; Soluble epoxide hydrolase

Indexed keywords

12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; COLLAGEN; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GLUTATHIONE DISULFIDE; HYDROLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART VENTRICLE REMODELING; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

ADAMANTANE; ANIMALS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEART FAILURE; HEMODYNAMICS; LAURIC ACIDS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

RATTUS;

EID: 84857632518     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.11.015     Document Type: Article

References (37)

1. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
2. Loehr L.R., Rosamond W.D., Chang P.P., Folsom A.R., Chambless L.E. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2008, 101:1016-1022.
3. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21. the EMPHASIS-HF Study Group.
4. Bellien J., Joannides R., Richard V., Thuillez C. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?. Pharmacol Ther 2011, 131:1-17.
5. Wang Y.X., Ulu A., Zhang L.N., Hammock B. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep 2010, 12:174-183.
6. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008, 18:20-25.
7. Monti J., Fischer J., Paskas S., Heinig M., Schulz H., Gösele C., et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008, 40:529-537.
8. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006, 103:18733-18738.
9. Ai D., Pang W., Li N., Xu M., Jones P.D., Yang J., et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 2009, 106:564-569.
10. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol 2009, 47:835-845.
11. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985, 72:406-412.
12. Litwin S.E., Katz S.E., Morgan J.P., Douglas P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994, 89:345-354.
13. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
14. Mellin V., Isabelle M., Oudot A., Vergely-Vandriesse C., Monteil C., Di Meglio B., et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005, 26:1544-1550.
15. Mulder P., Mellin V., Favre J., Vercauteren M., Remy-Jouet I., Monteil C., et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008, 29:2171-2179.
16. Fang Y., Favre J., Vercauteren M., Laillet B., Remy-Jouet I., Skiba M., et al. Reduced cardiac remodelling and prevention of glutathione deficiency after omega-3 supplementation in chronic heart failure. Fundam Clin Pharmacol 2011, 25:323-332.
17. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46:975-981.
18. Gao J., Bellien J., Gomez E., Henry J.P., Dautreaux B., Bounoure F., et al. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J Hypertens 2011, 29:1128-1135.
19. Hwang S.H., Tsai H.J., Liu J.Y., Morisseau C., Hammock B.D. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007, 50:3825-3840.
20. Fang X., Hu S., Watanabe T., Weintraub N.L., Snyder G.D., Yao J., et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 2005, 314:260-270.
21. Liclican E.L., Doumad A.B., Wang J., Li J., Falck J.R., Stier C.T., et al. Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. Hypertension 2009, 54:1284-1290.
22. Bauer W.R., Hiller K.H., Roder F., Rommel E., Ertl G., Haase A. Magnetization exchange in capillaries by microcirculation affects diffusion-controlled spin-relaxation: a model which describes the effect of perfusion on relaxation enhancement by intravascular contrast agents. Magn Reson Med 1996, 35:43-55.
23. Kober F., Iltis I., Izquierdo M., Desrois M., Ibarrola D., Cozzone P.J., et al. High-resolution myocardial perfusion mapping in small animals in vivo by spin-labeling gradient-echo imaging. Magn Reson Med 2004, 51:62-67.
24. Fang Y., Nicol L., Harouki N., Monteil C., Wecker D., Debunne M., et al. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol. J Mol Cell Cardiol 2011, 51:168-176.
25. Goulitquer S., Dréano Y., Berthou F., Corcos L., Lucas D. Determination of epoxyeicosatrienoic acids in human red blood cells and plasma by GC/MS in the NICI mode. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 876:83-88.
26. MacArthur P.H., Shiva S., Gladwin M.T. Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 851:93-105.
27. Vercauteren M., Remy E., Devaux C., Dautreaux B., Henry J.P., Bauer F., et al. Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure. Circulation 2006, 114:2498-2507.
28. Banquet S., Gomez E., Nicol L., Edwards-Lévy F., Henry J.P., Cao R., et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124:1059-1069.
29. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007, 82:60-67.
30. Suzuki S., Oguro A., Osada-Oka M., Funae Y., Imaoka S. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J Pharmacol Sci 2008, 108:79-88.
31. Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010, 85:413-423.
32. Saito T., Hu F., Tayara L., Fahas L., Shennib H., Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002, 283:H339-H345.
33. Liu Y.H., Carretero O.A., Cingolani O.H., Liao T.D., Sun Y., Xu J., et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005, 289:H2616-H2623.
34. Yan L., Lu L.Q., Wang H.X., Zeng X.J., Zhang L.K. Effect of 11, 12-epoxyeicosatrienoic acid on nitric oxide synthase of ischemia-reperfusion myocardium in rat. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005, 27:466-469.
35. Jiang J.G., Chen R.J., Xiao B., Yang S., Wang J.N., Wang Y., et al. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 2007, 82:162-174.
36. Fraccarollo D., Widder J.D., Galuppo P., Thum T., Tsikas D., Hoffmann M., et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008, 118:818-827.
37. Dhanasekaran A., Gruenloh S.K., Buonaccorsi J.N., Zhang R., Gross G.J., Falck J.R., et al. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 2008, 294:H724-H735.